Cellectis (CLLS) Capital Expenditures (QoQ) (2015 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Capital Expenditures (QoQ) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.53% |
| Mar 31, 2026 | 44.68% |
| Dec 31, 2025 | 59.44% |
| Sep 30, 2025 | -287.21% |
| Jun 30, 2025 | 22.78% |
| Mar 31, 2025 | 28.18% |
| Dec 31, 2024 | 83.28% |
| Sep 30, 2024 | -323.13% |
| Jun 30, 2024 | 776.15% |
| Mar 31, 2024 | 21.01% |
| Dec 31, 2023 | 78.44% |
| Sep 30, 2023 | -283.91% |
| Jun 30, 2023 | 426.76% |
| Mar 31, 2023 | 51.81% |
| Dec 31, 2022 | 87.48% |
| Sep 30, 2022 | -262.90% |
| Jun 30, 2022 | 446.17% |
| Mar 31, 2022 | -116.61% |
| Dec 31, 2021 | 99.09% |
| Sep 30, 2021 | -246.09% |